The 14th Annual Discovery on Target conference consists of a number of tracks, including one on genome editing. The genome editing programs starts of with a symposium on Understanding CRISPR: Mechanisms and Applications. It then shifts into a two part conference on Advances in Gene Editing and Gene Silencing.
Gene editing is rapidly progressing from being a research/screening tool to one that promises important applications downstream in drug development, cell and gene therapy. Cambridge Healthtech Institute’s symposium on Understanding CRISPR: Mechanisms and Applications will bring together experts from all aspects of basic science and clinical research to talk about how gene editing works and where it can be best applied. What are the different tools that can be used for gene editing, and what are their strengths and limitations? How does the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system compare to Transcription Activator-like Effector Nucleases (TALENs), zinc finger nucleases (ZFNs) and other alternative CRISPR-based systems? What do we now know about the biology of CRISPR and what lessons have we learnt from working with RNA interference (RNAi)-based systems? Scientists and clinicians from pharma/biotech as well as from academic and government labs will discuss the new findings in CRISPR mechanisms and share their experiences leveraging the utility of CRISPR-based gene editing for functional screening, disease modeling, and for creating cell and viral therapies.
Cambridge Healthtech Institute’s 13th annual two-part conference on Advances in Gene Editing and Gene Silencing will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies.
Part 1 will cover the use of CRISPR/Cas9 and RNAi for identifying new drug targets and therapies. It will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing and RNAi can be best applied. What are the different tools that can be used and what are their strengths and limitations? How does the CRISPR/Cas system compare to RNAi and other gene editing tools, such as Transcription Activator-like Effector Nucleases (TALENs) and zinc finger nucleases (ZFNs), and do they have any complementary uses? Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of gene editing for target discovery, disease modeling, and for creating cell and viral therapies.
Part 2 will cover the latest in the use of CRISPR/Cas9 and RNAi for functional screening. It will cover everything from assay design to data analysis when conducting low and high throughput screens and generating cellular models, both in vitro and in vivo, using CRISPR/Cas9, siRNA (small interfering RNA), and shRNA (short hairpin RNA), in a way that will evoke thought-provoking discussions and sharing of best practices. Screening experts from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of these diverse screening platforms for a wide range of applications.